secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001558370-22-017398
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor Q3 2022 net loss $6.4M, cash $46.6M; HOPE-3 enrollment on track
------------------------------------------------------------------------

- Revenue $1.6M from Nippon Shinyaku upfront recognition; net loss $0.26/shr vs $0.17/shr a year ago.
- Cash and securities $46.6M as of Sept 30, 2022, up from $34.9M at year-end 2021.
- Raised ~$1.9M through ATM at avg $5.72/shr; cash runway expected into Q2 2024.
- HOPE-3 Phase 3 for CAP-1002 in DMD enrollment progressing; interim analysis expected mid-2023.
- Positive one-year HOPE-2 open label extension data presented at WMS 2022; new StealthX exosome vaccine data shown.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837022017398/0001558370-22-017398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837022017398/capr-20221110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer